Maintenance Treatment Adherence Higher With Once-Daily COPD Combination Drug

January 4, 2019

Adherence was significantly more common in patients with chronic obstructive pulmonary disease (COPD) who initiated maintenance treatment with once-daily inhaled fixed-dose combination umeclidinium/vilanterol (UMEC/VI) compared with twice-daily fluticasone propionate/salmeterol (FP/SAL), according to a study published in the Journal of Managed Care & Specialty Pharmacy.

Noting that UMEC/VI led to greater improvement in lung function than FP/SAL in replicate clinical trials, researchers conducted this study to gauge real-world drug adherence among patients with COPD. Medication adherence was defined as 80% or more of days covered based on pharmacy dispensing data during the year following therapy initiation.

The study included 1386 patients who initiated UMEC/VI for COPD maintenance treatment and 3920 patients who initiated FP/SAL. The study population consisted of enrollees age 40 and older insured under commercial and Medicare Advantage with Part D plans from a large US health insurer database.

Treatment adherence among patients initiating UMED/VI was 29.1% compared with 17% for patients initiating FP/SAL, researchers reported. Adjusted odds of adherence were 2 times higher with UMEC/VI.

“[T]he odds of adherence were significantly higher among UMEC/VI versus FP/SAL new initiators,” researchers wrote.

The study, which was sponsored by GlaxoSmithKline, was presented at AMCP Nexus 2018.

Jolynn Tumolo


Moretz C, Stanford R, Hahn B, et al. Medication adherence to an inhaled fixed-dose combination long-acting muscarinic antagonist/long-acting beta-agonist or inhaled corticosteroid/long-acting beta-agonist in patients with COPD within a large US health insurer database. Journal of Managed Care & Specialty Pharmacy. 2018;24(10-a):S69.

For more Pharmacy Learning Network articles, visit the homepage